Bristol Myers is the latest large pharmaceutical company to stake an AI-computing superlative claim along those lines. Eli Lilly said in October it would work with Nvidia to build “the most powerful supercomputer owned and operated by a pharmaceutical company.” And they all need more AI power to do it. Under the expanded deal, Bristol Myers will deploy Nvidia’s DGX SuperPOD supercomputer with DGX Vera Rubin NVL72 systems, which will deliver up to “ten times greater performance per megawatt than its predecessor,” Bristol Myers stated. Giving a general-purpose agent access to the toolkit allows it to perform scientific tasks within the company’s “hybrid intelligence” model, which pairs researchers with AI agents, Kelleher added.